Completed PHASE1 INTERVENTIONAL 4-arm NCT01419457

Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment

A Phase I, Open-Label, Parallel-Group, Multiple-Dose Study to Determine the Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment and in Healthy Control Volunteers

Sponsor: MDVI, LLC

Conditions Healthy Hepatic Impairment

Interventions Favipiravir

Updated 7 times since 2017 Last updated: Oct 20, 2015 Started: Aug 31, 2011 Primary completion: Feb 28, 2013 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy and Hepatic Impairment, this trial is completed. The trial is conducted by MDVI, LLC and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MDVI, LLC

Data source: MDVI, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States
• Orlando, United States